Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fosun International Ltd.

Latest From Fosun International Ltd.

10 For 2020: Regulatory Trends To Watch In China

2019 was the year that China approved the first new drug for Alzheimer's in nearly two decades and for the first US approval of an original cancer drug from China. While the simmering US trade war has been addressed by a phase one agreement to be signed, other uncertainties marked a year dominated by a large vaccine scandal and resulting bankruptcy, and increasing calls to include China in global clinical development plans.

China Regulation

Biosimilar Boom in China Heralded By First Approval

Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.

China Biosimilars

US Tariffs On China Goods Also Target Diagnostics; Industry Preps For USTR Hearing

As more is learned about China-made medtech products facing a potential 25% US tariff, AdvaMed says some diagnostics would also take a hit and is working with its members to prepare for the upcoming US Trade Representative's public hearing on the impacts.

China United States

How China Regulatory Reforms Ring In International Biotechs' New Year

Just how much regulatory reforms help fuel biotech investment rush in China? Look no further than active deal flow and hot cash rolling in. The new regulations are all about bringing efficiency to their investment in China, industry insiders say.

Regulation Deals
See All

Company Information